Institutional members access full text with Ovid®

Share this article on:

Octreotide therapy for chylothorax in infants and children: A brief review

Helin, Radley D. DO, FAAP; Angeles, Sheila Therese V. MD; Bhat, Rama MD, FAAP

Pediatric Critical Care Medicine: November 2006 - Volume 7 - Issue 6 - p 576-579
doi: 10.1097/01.PCC.0000235256.00265.C8
Review Article

Objectives: We review physiology and pharmacology relating to the use of octreotide for chylothorax in infants and children. We review the published experience of octreotide dosing in this context.

Data Source: Systematic review of the literature, including PubMed (English-only journals), citations from relevant articles, major textbooks, and personal files.

Conclusions: Octreotide has been used as a successful therapeutic adjunct in a small number of neonatal cases and a larger number of pediatric cases. No consensus has been reached as to the optimal route of administration, dose, duration of therapy, or strategy for discontinuation of therapy. We suggest using higher doses (80–100 μg/kg/day) and initiating therapy early rather than using a low initial dose with upward titration. Duration of therapy required to elicit a significant response may vary between patients.

From the Department of Pediatrics, University of Illinois Medical Center at Chicago, Chicago, IL.

No financial support was obtained for this work. The authors have not disclosed any potential conflicts of interest.

©2006The Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies